Therefore, in view of the several adverse effects of high levels of PTH, a true uremic toxin, there is a need for closer monitoring for its levels in patients with CKD, in order to achieve more rigorous and early control of sHPT. This evidence concerns the gene PTH and chronic kidney disease.